Ministry endorses European warning on MS drug

Health Ministry adopts recommendations of European Medicines Agency on use of Gilenya (fingolimod).

By JUDY SIEGEL
January 22, 2012 22:58
1 minute read.
Drug company

Pharmacist pouring something 311. (photo credit: NATI SHOHAT/FLASH90)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The Health Ministry decided on Sunday to adopt the recommendations of the European Medicines Agency (EMA) regarding the use of Gilenya (fingolimod), a drug for treating the neurological autoimmune disease multiple sclerosis.

EMA is investigating a number of deaths that occurred not long after patients with relapsingremitting MS took the oral drug. The drug was added to Israel’s basket of medical technologies only a few weeks ago.

Be the first to know - Join our Facebook page.


The oral medication, developed and marketed by Novartis pharmaceuticals, competes with all other MS medications, including the Israeli-developed Copaxone and Rebif, which are injected by the patient on a daily basis. Gilenya, which was found to reduce the frequency and extent of neurological attacks, is a phospholipid, which captures lymphocytes in lymph nodes, thus preventing them from joining autoimmune attacks on nervous system.

The ministry in Jerusalem said there was one reported death in the United States of an MS patient who was taking fingolimod. There were also six other unexplained heart attacks deaths suspected of being connected to taking the oral drug.

Israeli doctors who have prescribed the drug have been advised to tell their MS patients who take Gilenya to report any side effects. The Health Ministry’s medical administration said that before patients start taking the drug they should undergo an electrocardiogram (EKG). After taking the pill for the first time, the patient should be watched via EKG for six hours. Blood pressure and pulse should be taken hourly six times after the first pill is swallowed.

If the patient suffers from brachycardia or other heart symptoms, the time the patient is directly observed could be extended, the ministry said. MS patients who have been prescribed Gilenya should report to the doctor immediately any heart problems such as chest pains, weakness or dizziness.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Holland Park’s forest, north of Eilat.
August 11, 2014
Promising trend of prosecution for environmental crimes, officials say

By SHARON UDASIN